Administer Cryoprecipitate
Based on the thromboelastography findings showing prolonged clot formation time and decreased α-angle with normal maximum amplitude, this patient has functional fibrinogen deficiency requiring immediate cryoprecipitate administration 1.
TEG Interpretation and Management Algorithm
The TEG pattern reveals:
- Normal reaction time = normal initiation of coagulation (adequate clotting factors II, V, VII, X, XI, XII)
- Prolonged clot formation time + decreased α-angle = impaired fibrin polymerization and clot formation kinetics
- Normal maximum amplitude = adequate platelet function and quantity
- Normal lysis at 30 minutes = no hyperfibrinolysis
This specific combination indicates functional fibrinogen deficiency despite the plasma fibrinogen level of 180 mg/dL being above the critical threshold of 150 mg/dL. The TEG is detecting functional impairment that standard laboratory values miss.
Why Cryoprecipitate is the Correct Answer
The 2023 European Trauma Guidelines explicitly recommend fibrinogen supplementation when "major bleeding is accompanied by hypofibrinogenemia (viscoelastic signs of a functional fibrinogen deficit or a plasma Clauss fibrinogen level ≤ 1.5 g/L)" 1. Your patient meets the first criterion with clear viscoelastic evidence of fibrinogen dysfunction.
Initial dosing: Administer 15-20 single donor units of cryoprecipitate (equivalent to 3-4 g fibrinogen concentrate) 1. This directly addresses the prolonged clot formation time and decreased α-angle.
Why NOT the Other Options
Fresh frozen plasma (FFP): The normal reaction time indicates adequate clotting factor levels. FFP is indicated when PT/APTT >1.5 times normal AND/OR viscoelastic evidence of clotting factor deficiency 1. This patient's INR of 1.5 is borderline, but the normal TEG reaction time confirms adequate factor levels. The guidelines specifically state "FFP use should be avoided for the correction of hypofibrinogenaemia" 1.
Tranexamic acid: The normal lysis at 30 minutes excludes hyperfibrinolysis. TXA should be given early in trauma (ideally within 3 hours) for bleeding patients 1, but this patient's TEG shows no fibrinolytic activity requiring antifibrinolytic therapy. Giving TXA without fibrinolysis increases thrombotic risk without benefit 2.
Platelets: The normal maximum amplitude indicates adequate platelet function and count. The platelet count of 150,000/μL is above the transfusion threshold of 50,000/μL for ongoing bleeding 1. Platelet transfusion is not indicated.
Red blood cells: While the hemoglobin of 7.5 g/dL warrants transfusion (target 70-90 g/L per guidelines 1), this does NOT address the coagulopathy shown on TEG. The question asks what to do based on the TEG findings—you must correct the coagulopathy first to stop bleeding, then transfuse RBCs.
Critical Pitfall to Avoid
Do not rely solely on the plasma fibrinogen level of 180 mg/dL. Research demonstrates that TEG can detect functional fibrinogen deficiency even when Clauss fibrinogen levels appear adequate 3. The prolonged clot formation time and decreased α-angle are direct measurements of impaired fibrin polymerization in real-time, which is more clinically relevant than static laboratory values in actively bleeding trauma patients.
Sequence After Cryoprecipitate
After administering cryoprecipitate:
- Repeat TEG to assess correction of clot formation time and α-angle 1
- Then address the anemia with RBC transfusion (target Hb 70-90 g/L)
- Continue massive transfusion protocol with goal-directed therapy based on serial TEG measurements 1
The patient is already on a massive transfusion protocol, so coordinate cryoprecipitate administration within that framework, but prioritize it based on the specific TEG abnormality identified.